Bismuth Subsalicylate

Overview

Bismuth subsalicylate (BSS; Pepto-Bismol®) is an oral antidiarrheal and gastroprotectant used in dogs and, with caution, in cats. It is commonly administered for acute, nonspecific diarrhea and as a component of triple or quadruple therapy protocols for the management of Helicobacter-associated gastrointestinal infections.

In veterinary patients, its clinical benefit is primarily localized to the gastrointestinal tract. The bismuth component provides mucosal protective, anti-endotoxic, and weak antimicrobial effects, while the salicylate portion contributes anti-inflammatory activity that may reduce intestinal secretion and improve clinical signs associated with secretory diarrhea.

Mechanism of Action (MOA): After oral administration, bismuth subsalicylate is believed to dissociate in the small intestine into bismuth salts and salicylate. The bismuth moiety exerts local protective and antimicrobial effects within the GI lumen, whereas the salicylate component inhibits prostaglandin synthesis, contributing to reduced intestinal inflammation and fluid secretion.

Indications

In dogs and cats, bismuth subsalicylate is used primarily as a gastrointestinal protectant and antidiarrheal agent. It is most appropriate for mild to moderate, uncomplicated diarrhea and as part of multimodal treatment protocols for specific GI infections.

• Acute nonspecific diarrhea: Used for short-term management of mild to moderate diarrhea to help reduce intestinal inflammation and fluid secretion.
• Gastroprotectant therapy: Provides mucosal protection in patients with gastric irritation or mild gastrointestinal inflammation.
• Helicobacter-associated infections: Included as a component of triple or quadruple therapy protocols in dogs and cats for management of Helicobacter GI infections.
• Adjunctive therapy: May be used alongside fluid and electrolyte therapy in patients with diarrhea, but it is not a substitute for appropriate supportive care.

Dosage (Reference)

Dog

In dogs, bismuth subsalicylate is most commonly administered as an oral suspension (17.5 mg/mL). It is used for short-term management of diarrhea and as part of combination therapy for Helicobacter-associated infections.

Cat

In cats, bismuth subsalicylate must be used cautiously due to potential salicylate absorption and increased sensitivity to salicylate-associated adverse effects. Lower end dosing and careful monitoring are advised.

Warnings & Precautions

Bismuth subsalicylate contains a salicylate component that may be systemically absorbed in dogs and cats. Although generally considered safe for short-term use in appropriate patients, careful case selection and monitoring are important, particularly in cats and in animals with underlying gastrointestinal or coagulation disorders.

• Salicylate sensitivity: Do not use in patients hypersensitive to aspirin or other salicylates. Systemic absorption of salicylate may occur and can contribute to adverse effects.
• Use in cats: Cats may be more sensitive to salicylates; use cautiously, if at all, and monitor closely for signs of toxicity.
• Bleeding disorders: Use cautiously in patients with preexisting coagulopathies, thrombocytopenia, or other bleeding disorders, as salicylates may increase bleeding risk.
• Gastrointestinal ulceration: May exacerbate underlying GI ulcers due to the salicylate component; avoid use in patients with known or suspected ulcer disease.
• Not a replacement for supportive care: Antidiarrheal therapy does not substitute for appropriate fluid and electrolyte therapy in patients with moderate to severe dehydration.
• Constipation or impaction: May cause constipation; fecal impaction is possible, particularly with prolonged use or in debilitated patients.
• Fecal discoloration: May change stool color to gray-black or greenish-black; this can mimic melena but does not necessarily indicate GI bleeding.
• Radiographic interference: Bismuth is radiopaque and may interfere with gastrointestinal radiographic examinations.
• Pregnancy: Salicylates are potential teratogens and may delay parturition; use with caution in pregnant animals.
• Nursing dams: Salicylates may be excreted in milk; use cautiously in lactating animals due to potential salicylate exposure in neonates.

Drug Interactions

Clinically relevant drug interactions with bismuth subsalicylate are primarily related to its salicylate component and to the ability of bismuth to interfere with absorption of certain orally administered drugs. Careful monitoring and dose adjustments may be required when used concurrently with the following medications in dogs and cats.

• Aspirin and other salicylates: Concomitant use may increase total salicylate serum concentrations and the risk of adverse effects, including gastrointestinal ulceration and bleeding.
• NSAIDs (e.g., carprofen, meloxicam, robenacoxib): Concurrent administration may increase the risk of gastrointestinal irritation, ulceration, and bleeding.
• Corticosteroids (e.g., dexamethasone, prednis(ol)one): May increase the risk of gastrointestinal bleeding; corticosteroids can also alter salicylate serum concentrations.
• Anticoagulants (e.g., heparin, rivaroxaban, warfarin): Increased risk of bleeding due to additive effects on platelet function and coagulation.
• Clopidogrel: Potential additive antiplatelet effects, increasing bleeding risk.
• ACE inhibitors (e.g., benazepril, enalapril): Salicylates may reduce the effectiveness of ACE inhibitors and enhance the risk of nephrotoxicity; monitor renal function and hydration status.
• Loop diuretics (e.g., furosemide): Salicylates may decrease the diuretic effect and increase salicylate serum concentrations.
• Methotrexate: Salicylates may displace methotrexate from plasma proteins, increasing the risk of methotrexate toxicity.
• Tetracycline antibiotics (e.g., doxycycline): Bismuth may decrease oral absorption of tetracyclines. If both are required, administer tetracycline first and separate administration by at least 2 hours (or give tetracycline 6 hours after bismuth if necessary).

Side Effects & Overdose

Side Effects

Adverse effects in dogs and cats are generally mild when bismuth subsalicylate is used short term and at recommended doses. Most effects are related to the salicylate component or to altered gastrointestinal motility.

• Fecal discoloration: Stool may appear gray-black or greenish-black. This is expected and should not be confused with melena unless other signs of GI bleeding are present.
• Constipation: May occur, particularly with repeated dosing; fecal impaction is possible in debilitated patients.
• Salicylate-associated effects: With excessive dosing or prolonged use, systemic salicylate absorption may result in lethargy, vomiting, diarrhea, or inappetence.
• Tongue discoloration: Temporary darkening of the tongue may occur due to bismuth.

Overdose

Overdose risk is primarily associated with the salicylate component. The standard 17.5 mg/mL suspension contains approximately 8.7 mg/mL of salicylate. Large or repeated supratherapeutic doses may result in salicylate toxicity or, at very high exposures, neurotoxicity.

• Dogs: Reported clinical signs include diarrhea, vomiting, lethargy, weakness, ataxia, and panting.
• Cats: Clinical signs may include diarrhea, lethargy, and inappetence; cats may be more sensitive to salicylate effects.
• Neurotoxicity: Very high doses of bismuth-containing products may contribute to neurologic signs.
• Management: Treatment is primarily supportive, including monitoring hydration status, providing fluid therapy as needed, and addressing electrolyte imbalances. Consultation with a veterinary poison control resource is recommended in suspected significant overdose cases.

Key Notes

Practical clinical points to optimize safe and effective use of bismuth subsalicylate in dogs and cats:

• Short-term therapy: Best suited for acute, uncomplicated diarrhea; lack of improvement within 24–48 hours warrants reassessment of diagnosis and treatment plan.
• Part of combination protocols: When used for Helicobacter-associated infections, it should always be included as part of a multidrug regimen rather than as monotherapy.
• Shake well before use: Suspension formulations must be mixed thoroughly before administration to ensure uniform dosing.
• Palatability tip: Refrigeration of the suspension may improve acceptance in some dogs and cats.
• Medication spacing: Avoid administering other oral medications within 2 hours unless specifically directed, to minimize interference with drug absorption.
• Owner communication: Advise owners to monitor appetite, energy level, and stool consistency, and to seek veterinary advice if diarrhea worsens or systemic signs develop.